582 related articles for article (PubMed ID: 10482928)
1. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.
Lefrere F; Makke J; Fermand J; Marolleau J; Dal Cortivo L; Alberti C; Mouton V; Benbunan M; Miclea J
Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928
[TBL] [Abstract][Full Text] [Related]
2. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
3. Delayed introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: retrospective study of 45 cases.
Dolgopolov I; Andreeva L; Yankelevich M; Mscheidze D; Siegel S; Mentkevich G
Am J Hematol; 2003 Aug; 73(4):225-9. PubMed ID: 12879423
[TBL] [Abstract][Full Text] [Related]
4. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
5. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.
Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL
Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
7. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
9. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients.
Kolbe K; Peschel C; Rupilius B; Després D; Burger K; Sklenar I; Färber L; Huber C; Derigs HG
Bone Marrow Transplant; 1997 Dec; 20(12):1027-32. PubMed ID: 9466274
[TBL] [Abstract][Full Text] [Related]
11. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
13. Successful mobilization of peripheral blood stem cells using recombinant human stem cell factor in heavily pretreated patients who have failed a previous attempt with a granulocyte colony-stimulating factor-based regimen.
Dawson MA; Schwarer AP; Muirhead JL; Bailey MJ; Bollard GM; Spencer A
Bone Marrow Transplant; 2005 Sep; 36(5):389-96. PubMed ID: 15980882
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma.
Hiwase DK; Bollard G; Hiwase S; Bailey M; Muirhead J; Schwarer AP
Cytotherapy; 2007; 9(6):539-47. PubMed ID: 17882718
[TBL] [Abstract][Full Text] [Related]
15. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma.
Martínez C; Sureda A; Martino R; Cancelas JA; Madoz P; García J; Brunet S
Bone Marrow Transplant; 1997 Nov; 20(10):855-8. PubMed ID: 9404926
[TBL] [Abstract][Full Text] [Related]
16. The use of G-CSF during first line chemotherapy adversely affects the yield of PBSC mobilization in non-Hodgkin's lymphoma patients.
Damiani D; Grimaz S; Sperotto A; Geromin A; Skert C; Cerno M; Rinaldi C; Fanin R
Adv Clin Path; 2002 Jan; 6(1):11-6. PubMed ID: 17582943
[TBL] [Abstract][Full Text] [Related]
17. Appropriate timing of G-CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT.
Xu L; Chang C; Li X; Gan W
J Clin Apher; 2009; 24(6):232-7. PubMed ID: 19899124
[TBL] [Abstract][Full Text] [Related]
18. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
[TBL] [Abstract][Full Text] [Related]
19. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
20. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]